CP-0127 (Deltibant) |
B2R antagonist |
Phase II |
Severe traumatic brain
injury sepsis |
Ineffective for sepsis. Discontinued due to unexpected
preclinical findings. |
[48] |
LF16-0687 (Anatibant) |
B2R antagonist |
Phase II |
Severe traumatic
brain injury |
Inconclusive results and possible safety issues. Trial
halted. |
[43] |
RMP-7 (Lobradimil) |
B2R agonist |
Phase II |
Childhood brain tumors |
Completed. No improved efficacy |
[49] |
|
|
Phase I |
HIV infection and cryptococcal meningitis |
Completed,
results not available |
NCT00002316 |
FOV-2304 (Safotibant) |
B1R antagonist |
Phase II |
Diabetic macular
edema |
Discontinued, results not available. |
[50,51] |
MK-0686 |
B1R antagonist |
Phase II |
Postherpetic neuralgia,
postoperative dental pain, osteoarthritis Terminated for postherpetic
neuralgia, completed for dental pain and osteoarthritis. |
No results
disclosed |
[50] |
BI-113823 |
B1R antagonist |
Phase I |
Osteoarthritis |
Terminated |
NCT01207973 |
SSR-240612 |
B1R antagonist |
Phase II |
Inflammation and neuropathic
pain |
Halted for undisclosed reasons. |
[52] |
B9870
(Breceptin)
Phase I
|
Dual B1R and
B2R antagonist
|
Phase I
|
Small cell lung cancer
|
No information available.
|
[50]
|